GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sangui Biotech International Inc (OTCPK:SGBI) » Definitions » Ending Cash Position

Sangui Biotech International (Sangui Biotech International) Ending Cash Position : $0.01 Mil (As of Mar. 2023)


View and export this data going back to . Start your Free Trial

What is Sangui Biotech International Ending Cash Position?

Sangui Biotech International's Ending Cash Position for the quarter that ended in Mar. 2023 was $0.01 Mil.

Sangui Biotech International's quarterly Ending Cash Position increased from Sep. 2022 ($0.01 Mil) to Dec. 2022 ($0.01 Mil) but then declined from Dec. 2022 ($0.01 Mil) to Mar. 2023 ($0.01 Mil).

Sangui Biotech International's annual Ending Cash Position increased from Jun. 2020 ($0.02 Mil) to Jun. 2021 ($0.03 Mil) but then stayed the same from Jun. 2021 ($0.03 Mil) to Jun. 2022 ($0.03 Mil).

Sangui Biotech International Ending Cash Position Historical Data

The historical data trend for Sangui Biotech International's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangui Biotech International Ending Cash Position Chart

Sangui Biotech International Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.03 0.02 0.03 0.03

Sangui Biotech International Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.03 0.01 0.01 0.01

Sangui Biotech International Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Sangui Biotech International's Ending Cash Position for the fiscal year that ended in Jun. 2022 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.029+0.00099999999999997
=0.03

Sangui Biotech International's Ending Cash Position for the quarter that ended in Mar. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.01+-0.003
=0.01

Sangui Biotech International Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Sangui Biotech International's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Sangui Biotech International (Sangui Biotech International) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sangui Biotech International Inc (OTCPK:SGBI) » Definitions » Ending Cash Position
Comparable Companies
SKYI BBBT DMKPQ CSTF CENBF ENDPQ PHBI THCT DKSC BLMS ZTS XTER:MRK TSE:4502 NSE:SUNPHARMA LSE:HLN VTRS XTAE:TEVA TSE:4507 XSWX:SDZ NBIX
Traded in Other Exchanges
SBH:Germany
Address
Bleichenbrucke 9, Hamburg, DEU, 20354
Website
http://www.sanguibiotech.com
Sangui Biotech International Inc develops pharmaceutical, medical and cosmetic products, through its subsidiary. The company develops oxygen carriers for providing oxygen transport in humans due to acute or chronic lack of oxygen and in the case of chronic wounds. It has also developed external applications of oxygen transporters in the form of sprays for healing chronic wounds and gels and emulsions for the regeneration of the skin. The products offered are artificial oxygen carriers; Chitoskin wound pads; and haemoglobin-based wound spray technology sold under the brand name Granulox. It derives revenue from licensing fees on sales of its wound spray product.
Executives
Hubertus Schmelz director NEUER WALL 54, HAMBURG 2M D-20354
Joachim Fleing director ALFRED HERRHAUSENSTR 44, WITTEN 2M 58455
Thomas Striepe director NEUER WALL 54, HAMBURG 2M D-20354
Wolfgang Barnikol director ALFRED HERRHAUSEN STR 44, WITTEN 2M 58455
Lutz Joachim director ALFRED-HERRHAUSEN-ST. 44, WITTEN 2M 58455
Christoph Ludz director SANDERSKOPPEL 17, HAMBURG 2M 22391

Sangui Biotech International (Sangui Biotech International) Headlines

No Headlines